Share this Page:
Maintaining good health-related quality of life is important for all people who are having cancer treatment. This study looks at the quality of life of patients who are being treated with a combination of lenvatinib plus everolimus in a phase 2 clinical trial.
Health-related quality of life information was collected from patients who started treatment with two different doses of lenvatinib, 14 mg or 18 mg daily in combination with 5 mg of everolimus. The study also compared the safety and efficacy of the two different starting doses of lenvatinib in combination with everolimus. All patients had already been treated with a vascular endothelial growth factor (VEGF) targeted treatment.
The researchers were looking at changes from the start of the study (baseline) using three different quality of life questionnaires. There were 343 patients in the study who were randomly allocated to be given 18 mg or 14 mg of lenvatinib plus 5 mg everolimus. Average time to deterioration of health was longer for the patients in the 18 mg group than those in the 14 mg group.
Patients treated with 18 mg lenvatinib starting dose had a more favourable health-related quality of life and longer time to deterioration of their health than those treated with 14 mg starting dose.